News | Artificial Intelligence | November 13, 2018

Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018

Deep learning algorithms designed for faster scans and reduced radiation dose

Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018

November 13, 2018 — At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical will showcase SubtlePET, its artificial intelligence (AI)-powered technology. SubtlePET allows hospitals and imaging centers to deliver a faster and safer patient scanning experience, while enhancing exam throughput and provider profitability. The software is currently under U.S. Food and Drug Administration (FDA) 510k review and in pilot use in multiple university hospitals and imaging centers in the U.S. and abroad.

SubtlePET leverages AI to allow hospitals and imaging centers to accelerate positron emission tomography (PET) scan times four-fold or reduce PET radiation dose by up to 75 percent, according to the company.

A second product pending FDA submission is SubtleMRI, which allows imaging centers to significantly accelerate magnetic resonance imaging (MRI) scans. Subtle Medical’s focus on image acquisition and workflow differentiates it from most AI imaging companies, which are focusing on post-processing and computer-aided diagnosis.

Subtle Medical technology utilizes deep learning algorithms that integrate seamlessly with any original equipment manufacturer (OEM) PET and MRI scanners to enhance images during acquisition without any interruption or alteration in the imaging specialists’ workflow.  The result is shorter scan duration or less exposure to radiation, which is particularly beneficial for children and those undergoing repeat PET exams.

In March 2018, Subtle Medical received the NVIDIA Inception Award Top Healthcare+AI Startup Globally from among over 3,000 AI contenders. The company was also selected as the first AI+healthcare startup for Bessemer Venture Partner’s Deep Health Seed Program.

Subtle Medical’s core technology was developed at Stanford University.  The company has licensed multiple patented technologies invented by the founders at Stanford as well as medical imaging datasets acquired during clinical research at Stanford radiology labs.

At RSNA 2018, Subtle Medical’s co-founders will be participating in research and industry presentations along with other academic collaborators from Stanford. Presentations include:

Lunch and Learn: Thinking Faster, Safer, & Smarter: How You Can Use AI to improve MR and PET Imaging Efficiency, Patient Satisfaction, and Safety

Greg Zaharchuk, M.D., Ph.D. |Chris Hess, M.D., Ph.D. | Paul Chang, MS, M.D. | Michael Brant-Zawadzki, M.D., FACR

Wednesday 12:30-1:30 PM | LL33  

 

Machine Learning Theater: AI Improves Imaging Workflow for MR and PET Exams: Faster, Safer, and Smarter

Greg Zaharchuk, M.D., Ph.D. |Enhao Gong, Ph.D.

Monday 12:00-12:20 PM | ML23

 

Evaluation of Deep-Learning-Based Technology for Reducing Gadolinium Dosage in Contrast-Enhanced MRI Exams

Enhao Gong, Ph.D. | Jonathan Tamir, BSC | John Pauly | Max Wintermark, M.D. | Greg Zaharchuk, M.D., Ph.D.

Physics (MR: New Techniques, Systems, Evaluation)

Monday 10:30-12:00 PM | SSC12 | Presentation 9 of 9

 

Does 18F-FDG Dose Reduction for PET/MRI Affect Treatment Response Assessment of Lymphomas and Sarcomas?

Ketan Yerneni |Anne Muehe, M.D. | Praveen Gulaka, Ph.D. | K. Elizabeth Hawk, M.D., Ph.D. | Ashok Joseph Theruvath, M.D. | Heike Daldrup-Link, M.D.

Monday 12:45-1:15 PM | PD218-SD-MOB4

 

Stroke Outcome Prediction from Meta Information Available at Patient Admission

Yuan Xie | Bin Jiang | Enhao Gong, Ph.D. | Ying N. Li | Guangming Zhu | Bo Zhou | Patrik Michel | Max Wintermark, M.D. | Greg Zaharchuk, M.D., Ph.D.

Neuroradiology Series: Stroke

Wednesday 8:30-12:00 PM | RC505 | Presentation 10 of 12

 

Deep Learning Segmentation for Detection of Brain Metastases in the Small Data Regime

Daniel L. Rubin, M.D., MS | Greg Zaharchuk, M.D., Ph.D. | Michael Iv, M.D. | Rhea Singh

Neuroradiology (Dots and Dashes: Image Analysis in Neuroradiology)

Thursday 10:30-12:00 PM | SSQ15 | Presentation 8 of 9

For more information: www.subtlemedical.com

 

Related Content

John Carrino, M.D., M.Ph., presents “Challenges and Opportunities for Radiology to Prove Value in Alternative Payment Models” at AHRA 2019

John Carrino, M.D., M.Ph., presents “Challenges and Opportunities for Radiology to Prove Value in Alternative Payment Models” at AHRA 2019. Photo by Greg Freiherr

Feature | Radiology Business | July 22, 2019 | By Greg Freiherr
Efforts to reform healthcare are booming, b
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
Johns Hopkins Named Qualified Provider-led Entity to Develop Criteria for Diagnostic Imaging
News | Clinical Decision Support | July 18, 2019
On June 30, 2019, the Centers for Medicare & Medicaid Services (CMS) announced the Johns Hopkins University School...
Anatomage Releases Anatomage Cloud Platform
News | Remote Viewing Systems | July 16, 2019
Anatomage Inc. released an update to the Anatomage Cloud platform that allows medical and dental professionals to...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...